Legalese Disclosure
Individuals, not legal entities, may save one copy of these presentation slides for personal, non commercial purposes only. No other uses of these materials, in whole or in part, are allowed. This includes, but is not limited to, commercial use, reproduction, retransmission, sharing, editing, or creating of derivative works, without the prior written permission of HFSA. Permission may be requested by contacting education@hfsa.org.
Program Overview
Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of major adverse heart failure (HF)-related events and improve quality of the life (QQL) in individuals with HF. Beneficial effects of SGLT2 inhibition in HF patients have been demonstrated early after initiation of therapy, through the spectrum of left ventricular ejection fraction (LVEF), in patients with and without diabetes, and regardless of care setting, with excellent safety and tolerability. In addition, SGLT2 inhibitors slow the progression of kidney disease in HF patients (and in individuals with chronic kidney disease (CKD) without HF).
Despite robust data which has facilitated their incorporation into HF clinical practice guidelines as foundational therapy through the range of EF, clinical inertia is still a major reason why implementation of SGLT2 inhibitors therapy is suboptimal. Therefore, to address the needs of HF clinicians, this educational initiative will provide case-based learning (after brief summaries of clinical evidence) and commentary by leading HF experts on implications of use of SGLT2 inhibitors in everyday clinical practice.
Educational Objectives
Upon completion of this activity, participants should be able to:
1. Discuss the evidence from the SGLT2 inhibitors trials in patients with HFrEF.
2. Describe the data from clinical studies with SGLT2 inhibitors in patients with HF with mildly reduced ejection fraction and HF with preserved ejected fraction.
3. Explain the implications and key messages for using SGLT2i in clinical practice.
Target Audience
This educational activity is intended for clinicians treating patients with heart failure.
Agenda
Introduction
Muthiah Vaduganathan, MD, MPH (Chair)
SGLT2 Inhibitors for Patients with HFrEF
Muthiah Vaduganathan, MD, MPH
Case Presentation #1: SGLT2i for a Patient with HFrEF
Stephen Greene, MD
SGLT2 Inhibitors for Patients with HFmrEF, HFpEF
Mikhail Kosiborod, MD
Case Presentation #2: SGLT2i for a Patient with HFpEF
Alanna Morris, MD, MSc
Implications/Key Messages for Clinical Practice
Muthiah Vaduganathan MD, MPH
Question and Answer
Accreditation and Credit Designation Statements
Physicians: In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of
1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists: The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.25 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-H04-P.
Disclosure StatementIt is the policy of the Heart Failure Society of America (HFSA) to ensure balance, content independent of industry influence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).
Faculty Disclosures
ChairMuthiah Vaduganathan, MD, MPH
FacultyStephen Greene, MD
Mikhail Kosiborod, MD
Alanna Morris, MD, MSc
Muthiah Vaduganathan
|
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? YES
|
Company Name
|
Type of Company
|
Relationship
|
Other
|
Has this relationship ended?
|
|
Other Company - American Regent, AstraZeneca, Bayer AG, Boehringer Ingelheim, Novartis, Roche Diagnostics, Galmed, Occlutech, and Impulse Dynamics
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Other Company - American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Other Company - AstraZeneca, Boehringer Ingelheim, Cytokinetics, Novartis, Roche Diagnostics
|
Pharmaceutical Company/Distributors
|
Speaker's Bureau
|
|
Current
|
|
|
3. I have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated by participants for fair balance. I AGREE
Stephen Greene
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? YES
|
Name
|
Type of Company
|
Relationship
|
Other
|
Has this relationship ended?
|
|
Amgen
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Ended
|
|
Bayer AG
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
AstraZeneca
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Bristol-Myers Squibb
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Boehringer Ingelheim
|
Pharmaceutical Company/Distributors
|
Speaker's Bureau
|
|
Current
|
|
Cytokinetics
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Novartis
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Vifor Pharma
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Roche
|
Diagnostic Lab
|
Advisory Panel
|
|
Current
|
|
sanofi-aventis
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Merck
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Tricog Health
|
Bio-Medical Startup
|
Consultant
|
|
Current
|
|
Bristol-Myers Squibb
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
AstraZeneca
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Merck
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Boehringer Ingelheim
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Boehringer Ingelheim
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - PharmaIN
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Lexicon Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
scPharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
|
I have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated by participants for fair balance. I AGREE
|
Mikhail Kosiborod
|
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? YES
|
Company Name
|
Type of Company
|
Relationship
|
Other
|
Has this relationship ended?
|
|
Alnylam Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Amgen
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Applied Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
AstraZeneca
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
AstraZeneca
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Bayer AG
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Boehringer Ingelheim
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Boehringer Ingelheim
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Cytokinetics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Eli Lilly
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Esperion Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Janssen
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Lexicon Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Merck
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Novo Nordisk
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Pharmacosmos
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Sanofi
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Vifor Pharma
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - 35Pharma
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Dexcom
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Imbria Pharmeceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
scPharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Structure Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Youngene Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Artera Health
|
Pharmaceutical Company/Distributors
|
Other Relationship
|
Holder of stock options
|
Current
|
|
Other Company - Saghmos
|
Pharmaceutical Company/Distributors
|
Other Relationship
|
Holder of stock options
|
Current
|
|
|
I have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated byparticipants for fair balance. I AGREE
|
|
|
Alanna Morris
|
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? NO
|
|
have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated by participants for fair balance. I AGREE
|
|
|
|
Educational Grant
Voxmedia and the Heart Failure Society of America (HFSA) gratefully acknowledge the educational grant from AstraZeneca Pharmaceuticals.